Clinical Q, Bottom Line, Primary Outcome 1) ARDS

Question 1

ACURASYS Clinical Questions

Answer 1

Does administration of cisatracurium improve survival when compared to placebo in ICU patients undergoing mechanical ventilation for early severe ARDS?

Question 2

ACURASYS Bottom Line

Answer 2

Paralysis with cisatracurium for 48 hours in patients with early severe ARDS improves 90 day survival and increases ventilator-free days.

Question 3

ACURASYS Primary Outcome

Answer 3

Mortality before discharge or 90 days

Question 4

ARDSNet Clinical Q

Answer 4

In patients with ALI/ARDS receiving mechanical ventilation, how does a lung protective strategy using lower tidal volumes compare with traditional ventilation protocols in decreasing mortality and ventilator-free days?

Question 5

ARDSNet Bottomline

Answer 5

In patients with ARDS, low tidal volume ventilation (initial TV 6ml/kg PBW) had lower mortality and more ventilator-free days.

Question 6

ARDSNet Primary Outcome

Answer 6

ventilator free days, mortality at 120 days

Question 7

FACTT Clinical Q

Answer 7

In patients with ALI/ARDS that are intubated and receiving positive pressure ventilation, how does the conservative compare to the liberal fluid management strategy in reducing mortality?

Question 8

FACTT Bottom Line

Answer 8

Among patients with ALI/ARDS, a conservative fluid management strategy targeting a CVP <4 mmHg improves lung function, decreases ventilator days, and reduces ICU days compared to a liberal strategy

Question 9

FACTT primary outcome

Answer 9

All cause mortality at 60 days

Dialysis at 60 days